Journey Medical 10-Q: Q3 Revenue $19.0M, Going-Concern Doubt Persists
DERM sits 15% above its 52-week low of $4.25.
Summary
Journey Medical's Q3 10-Q confirms $19.0M revenue (up 8%) and $9.0M Emrosi sales, but keeps the going-concern warning, shows cash down to $22.3M, and moves $7.5M of term debt to short-term ahead of February 2027 principal payments.
Key Events · Earnings and Guidance · DERM
-
Q3 Revenue $19.0M, Emrosi Up 84%
Total revenue was $19.0M versus $17.6M a year ago, with Emrosi contributing $9.0M versus $4.9M; Qobrexza fell to $5.6M from $7.4M.
-
Going-Concern Doubt Persists
The 10-Q states substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance due to recurring losses.
-
Cash Falls to $22.3M
Cash and equivalents were $22.3M at September 30, 2026 versus $24.1M at December 31, 2025; net cash used in operations was $2.3M for the nine months.
-
$7.5M Term Loan Now Short-Term
Of the $25.0M SWK principal, $7.5M is classified short-term as quarterly principal payments of $2.5M begin February 2027, with $10.0M due in 2027 and $16.25M in 2028 including the exit fee.
Analysis · DERM · Life Sciences
The 10-Q confirms the Q3 numbers already released today but adds the full financial picture, and the key fact is that substantial doubt about the company's ability to continue as a going concern remains in the filing. Cash fell to $22.3M from $24.1M at year-end, and $7.5M of the $25.0M SWK term loan is now classified short-term because principal payments start February 2027. A $4.1M vendor settlement consumed cash in the quarter, with $1.7M above the prior accrual hitting SG&A. Revenue growth is real — Emrosi at $9.0M, up 84% — but the runway and the 2027 debt amortization are what determine whether the equity needs another raise.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DERM was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.9M. The 52-week trading range was $4.25 to $9.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.